Currently, a prospective phase II pilot study of [177Lu]Lu-PSMA-I&T for ACC and SDC patients is recruiting (NCT04291300) offering a maximum of four cycles containing 7.4 GBq, every 6 weeks. Here, FOLH1 is linked to adrenal cortex carcinoma.